



01-12-06

AF/1646  
ZPWExpress Mail No.: EV 475 142 167 US**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**Application of: Ish-Horowicz *et al.*

Confirmation No.: 8177

Serial No.: 09/783,931

Art Unit: 1646

Filed: February 15, 2001

Examiner: Claire M. Kaufman

For: ANTIBODIES TO VERTEBRATE DELTA  
PROTEINS AND FRAGMENTS

Attorney Docket No: 7326-122

**AMENDMENT FEE TRANSMITTAL SHEET**Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The fee required to be filed with the accompanying amendment of even date herewith concerning the above-identified application has been estimated to be \$0.00.

Please charge any required fee to Jones Day Deposit Account No. 50-3013. A copy of this sheet is enclosed for accounting purposes.

Respectfully submitted,

Date: January 10, 2006  
Adriane M. Antler32,605  
(Reg. No.)

By:

  
William J. Thorman40,203  
(Reg. No.)**JONES DAY**  
222 East 41<sup>st</sup> Street  
New York, New York 10017  
(212) 326-3939



**Express Mail No. EV 475 142 167 US**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: Ish-Horowicz *et al.*

Confirmation No.: 8177

Serial No.: 09/783,931

Art Unit: 1646

Filed: February 15, 2001

Examiner: Claire M. Kaufman

For: ANTIBODIES TO VERTEBRATE DELTA  
PROTEINS AND FRAGMENTS

Attorney Docket No: 7326-122

**AMENDMENT UNDER 37 C.F.R. § 1.116**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In response to the outstanding Office Action, dated November 10, 2005, please enter the following amendments and consider the remarks made below in connection with the above-identified patent application. Submitted concurrently herewith are (a) an Amendment Fee Transmittal Sheet; (b) a copy of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures; and (c) a third substitute Sequence Listing in paper and computer-readable forms.

**Amendments to the Specification** begin on page 2 of this paper.

**Amendments to the Claims** begin on page 3 of this paper.

**Remarks** begin on page 20 of this paper.